Greenwich Lifesciences Inc. saw a price increase of 30.75% in pre-market trading, reaching a 20-day high. This surge is attributed to the company's announcement of an 80% reduction in breast cancer recurrence rates observed in the FLAMINGO-01 trial, which involved 250 non-HLA-A*02 patients. The promising results highlight the potential of GLSI-100 immunotherapy, which could significantly impact breast cancer treatment paradigms.
The positive movement aligns with broader market strength, as the Nasdaq-100 rose 0.53% and the S&P 500 gained 0.46%. The trial's success not only demonstrates the efficacy of GLSI-100 but also positions Greenwich Lifesciences favorably in the competitive landscape of breast cancer therapies, likely attracting more investment and attention.
Overall, the impressive trial results and the stock's performance indicate a strong market interest in GLSI-100, suggesting that the company may be on the verge of a breakthrough in breast cancer treatment.
Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 47.50 USD with a low forecast of 45.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 47.50 USD with a low forecast of 45.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 28.590
Low
45.00
Averages
47.50
High
50.00
Current: 28.590
Low
45.00
Averages
47.50
High
50.00
H.C. Wainwright
Buy
upgrade
$39 -> $50
2025-12-30
Reason
H.C. Wainwright
Price Target
$39 -> $50
AI Analysis
2025-12-30
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Greenwich LifeSciences to $50 from $39 and keeps a Buy rating on the shares. The firm cites the positive efficacy in the non-HLA-A*02 arm of the ongoing Phase 3 FLAMINGO-01 trial of GLSI-100 in breast cancer for the target boost. GLSI-100 reduced breast cancer recurrence by 80% in the non- HLA-A*02 arm, the analyst tells investors in a research note. H.C. Wainwright views the preliminary data as "highly encouraging," saying it could double the market for GLSI-100.
Noble Capital
Outperform
initiated
$45
2025-08-20
Reason
Noble Capital
Price Target
$45
2025-08-20
initiated
Outperform
Reason
Noble Capital initiated coverage of Greenwich LifeSciences with an Outperform rating and $45 price target. Greenwich is developing GSLI-100, which has completed four clinical trials that lead to the design of the current Phase 3 Flamingo-01 trial for prevention of breast cancer recurrence in high-risk patients, the analyst tells investors. The firm, which estimates market entry by FY28, sees \"large market potential\" for GLSI-100.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GLSI
Unlock Now
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$38 → $39
2025-04-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$38 → $39
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$38
2025-02-11
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$38
2025-02-11
Reiterates
Strong Buy
Reason
About GLSI
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
